FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
PhaseRx, Inc. Stock AnalysisComprehensive stock analysis for PhaseRx, Inc. (PZRXQ) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPZRXQ
PZRXQ
PhaseRx, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PZRXQ
Home🔹Stocks🔹PhaseRx, Inc.

PhaseRx, Inc.

PZRXQ•OTC

PhaseRx, Inc.

PZRXQ•OTC
Market cap
$1.17K
Sentiment

Your view on PZRXQ

Mkt Cap
$1.17K
Sentiment
Your view
PZRXQ
PhaseRx, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PZRXQ
Company Overview

Overview

What the company does, where it operates, and who runs it.

About PhaseRx, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Robert W. Overell
Headquarters
410 West Harrison Street, Seattle, WA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Robert W. Overell
Headquarters
410 West Harrison Street, Seattle, WA, US
Description

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News